Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes
B F
BF
Department of Medicine, Duke University Arthritis Center, Durham, NC.
Yasutomi
Y
Y
Torres
J V
JV
Gardner
M B
MB
Langlios
A J
AJ
Bolognesi
D P
DP
Matthews
T J
TJ
Scearce
R M
RM
Jones
D M
DM
Moody
M A
MA
D016915:AIDS Vaccines / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control; D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D006801:Humans; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D010455:Peptides / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments; D010455:Peptides